Sentiment Trading

Novo Nordisk B, a leading Danish pharmaceutical company, is undergoing a major governance overhaul after a prolonged dispute with its primary shareholder, the Novo Nordisk Foundation, over the future composition and strategic direction of the board.

Novo Nordisk’s stock price plummeted 6.4% after former US President Donald Trump announced a plan to reduce tariffs on fertility treatments and the medication Ozempic, potentially undermining the company’s pricing power in the US market.